Pharmacists in Cross City, FL Accepting Medicare
1 Pharmacists found. Showing 1 - 1
 Sandipkumar Patel Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 16734 S E Us Hwy 19, Cross City, FL 32628 Phone: 352-498-3342 Fax: 352-498-4111 |
News Archive
Incidence and severity emerging CVD risk factors may differ between genders
The incidence and severity of both traditional and emerging cardiovascular disease (CVD) risk factors as well as the response to treatment may differ between genders. In this narrative review, several emerging CVD risk factors (i.e. inflammatory and haemostatic markers, endothelial dysfunction, homocysteine, lipid disorders, microalbuminuria/proteinuria, coronary artery calcium score, arterial stiffness, periodontitis, inflammatory bowel syndrome, obstructive sleep apnea, impaired glucose metabolism, metabolic syndrome and non-alcoholic fatty liver disease) are discussed in the context of gender differences.
The soon-to-be-released GOP budget plan: What will become of traditional Medicare?
How this question is answered could have big implications for the GOP's presidential and congressional candidates. Meanwhile, Politico Pro reports the plan being prepared by House Budget Committee Chairman Paul Ryan, R- Wis., is likely to include a reserve fund to deal with Medicare's sustainable growth rate formula.
Settling controversy surrounding bird flu research will not be easy
The WHO is expected to hold a meeting in February to discuss controversy over recent research on the H5N1 bird flu virus, after the U.S. National Scientific Advisory Board for Biosecurity (NSABB) in December advised the journals Science and Nature to withhold publishing two teams' research on the virus for fear the information could "fall into the wrong hands," a commentary in the Economist's "Babbage" blog states.
Suneva Medical to present interim data from its Artefill study for NLF correction at the Maui Derm 2010
Suneva Medical, a privately-held aesthetic medical device company, today announced 18-month interim results from its prospective, open-label, five-year safety and patient satisfaction study on Artefill for nasolabial fold (NLF) correction. The study assessed adverse events with Artefill starting at 6-months post treatment. Initial results show the incidence of adverse events with Artefill compare favorably to the current label, and that the majority of patients (88%) reported a high satisfaction rating. Upon completion, this will be the largest and longest duration prospective U.S. clinical study of any dermal filler.
Antiretroviral drug efavirenz associated with better outcomes in HIV-infected adults
A study led by researchers at the Johns Hopkins Bloomberg School of Public Health found that HIV-infected patients taking the antiretroviral drug efavirenz were more likely to adhere to treatment and less likely to experience virologic failure and death compared to patients taking nevirapine.
› Verified 8 days ago